GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Operating Margin %

GYRE (Gyre Therapeutics) Operating Margin % : 2.38% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Gyre Therapeutics's Operating Income for the three months ended in Dec. 2024 was $0.7 Mil. Gyre Therapeutics's Revenue for the three months ended in Dec. 2024 was $27.9 Mil. Therefore, Gyre Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 was 2.38%.

The historical rank and industry rank for Gyre Therapeutics's Operating Margin % or its related term are showing as below:

GYRE' s Operating Margin % Range Over the Past 10 Years
Min: 9   Med: 16.15   Max: 33.64
Current: 15.35


GYRE's Operating Margin % is ranked better than
86.39% of 992 companies
in the Biotechnology industry
Industry Median: -127.94 vs GYRE: 15.35

Gyre Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Gyre Therapeutics's Operating Income for the three months ended in Dec. 2024 was $0.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $16.2 Mil.


Gyre Therapeutics Operating Margin % Historical Data

The historical data trend for Gyre Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Operating Margin % Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Operating Margin %
33.64 9.00 16.94 15.35

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -19.11 29.70 12.93 16.61 2.38

Competitive Comparison of Gyre Therapeutics's Operating Margin %

For the Biotechnology subindustry, Gyre Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Operating Margin % falls into.


;
;

Gyre Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Gyre Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=16.229 / 105.757
=15.35 %

Gyre Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0.663 / 27.872
=2.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gyre Therapeutics  (NAS:GYRE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Gyre Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics Business Description

Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.